Give you a brief introduction to nmnh powder | BONTAC

Give you a brief introduction to nmnh powder | BONTAC

NMNH effectively increased cellular NAD+ content and this process was mainly Dependent on NMNAT NMNH effectively increased cellular NAD+ content and this process was mainly Dependent on NMNAT NMNH is naturally present in the kidney, NMNH is rapidly converted to NAD+ in biological cells at a rate and concentration more than twice that of NMN, while elevating NAD+ levels in a variety of tissues. NMNH reduces cellular damage in the presence of hypoxia and enhances cellular repair. In addition, NMNH also significantly increases NADH levels in biological cells and inhibits cellular glycolysis and the tricarboxylic acid cycle.
Get A Quote

Advantages of NMNH

NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service

Advantages of NADH

NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service

Advantages of NAD

NAD:  1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products

Advantages of MNM

NMN:  1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University

about us

We Have The Best Solutions for Your Business

Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.

As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.

In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.

Learn More

NMNH is more potent than NMN

When applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective , as at 500 µM concentration, it achieved “an almost 10-fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.

NMNH is more potent than NMN

BONTAC NMNH product features and advantages

1. "Bonzyme" Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3. Exclusive “Bonpure” seven-step purification technology, high purity (up to 99%) and stability of production of NMNH powder
4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5. Provide one-stop product solution customization service

BONTAC NMNH product features and advantages

NADH powder manufacturing method

The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme becomes the mainstream method owing to the advantages of pollution free, high level of purity and

NADH powder manufacturing method
User Reviews

What users say about BONTAC

BONTAC is a reliable partner that we have been working with for many years. The purity of their coenzyme is very high. Their COA can achieve relatively high test results.

Front

I discovered BONTAC in 2014 because David's article in cell about NAD and NMN related showed that he used BONTAC's NMN for his experimental material. Then we found them in China. After so many years of cooperation, I think it is a very good company.

Hanks

I think green, healthy and high purity are the advantages of BONTAC's products compared with others. I still work with them to this day.

Phillip

In 2017, we chose BONTAC's coenzyme, during which our team encountered many technical problems and consulted their technical team, which were able to give us good solutions. Their products are shipped very fast and they work more efficiently.

Gobbs
Frequently Asked Question

Do you have any question?

NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.

First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.

Our updates and blog posts

The Nuanced Role of NADPH in the Complex Landscape of Metabolic Disorders

1.Introduction Nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), also known as reduced coenzyme II, is a critical cofactor in cellular antioxidant systems and lipid synthesis, which links insulin resistance and ferroptosis of pancreatic β cells in the context of metabolic disorders such as diabetes mellitus, playing a central role in maintaining metabolic homeostasis. 2. Biological role of NADPH NADPH functions as a coenzyme essential to cellular metabolism, playing pivotal roles in various critical biological processes, such as ROS scavenging, ROS production, fatty acid synthesis and cholesterol synthesis.   3. Biosynthetic pathway of NADPH Cellular production of NADPH is facilitated through several pathways, including the pentose phosphate pathway, the citric acid cycle, and fatty acid metabolism. The dynamic equilibrium between NADPH synthesis and consumption is essential for preserving cellular redox balance and enabling a host of biosynthetic reactions. 4. The role of NADPH in insulin secretion from pancreatic β-Cells Both redox reaction and metabolic signaling can modulate insulin secretion from pancreatic β-cells, where NADPH plays a central role. It can not only serves as a metabolic coupling factor, but also acts as a custodian of β-cell integrity, delicately managing the interplay between metabolic inputs and insulin output. 5. The interaction between insulin resistance and NADPH A substantial body of evidence reveals that NADPH is critical for the regulation of oxidative stress and inflammatory responses, the main contributors to the pathogenesis of insulin resistance. Specifically, NADPH is implicated in ROS production via NOX and is also utilized in the synthesis of new fatty acids, which contributes to the development of insulin resistance, particularly in the context of obesity-induced chronic inflammation. 6. The impact of NADPH upon the ferroptosis in the context of diabetes In pancreatic β cells, the elevated blood sugar and pro-inflammatory cytokines can trigger oxidative stress and iron accumulation to promote lipid peroxidation, thereby facilitating the ferroptosis. In return, the ferroptosis can reduce insulin secretion and beta cell mass, which is contributive to the progression of diabetes.  In general, NADPH plays a dual role in ferroptosis. On the one hand, it can promote ROS generation via NOX. On the other hand, it can support antioxidant defense through glutathione regeneration. In the context of diabetes, NADPH may predominantly fuel processes leading to ferroptosis, mainly due to the enhanced activity and affinity of NOX, which however requires further research for verification. 7. Conclusion NADPH has a critical role in the complex landscape of metabolic disorders, particularly insulin resistance and ferroptosis. Regulating NADPH-related pathways may open up new opportunities for the treatment of metabolic disorders. Reference Moon, Dong-Oh. “NADPH Dynamics: Linking Insulin Resistance and β-Cells Ferroptosis in Diabetes Mellitus.” International journal of molecular sciences vol. 25,1 342. 26 Dec. 2023, doi:10.3390/ijms25010342 Production advantages and features of BONTAC NADPH BONTAC has rich R&D experience and advanced technology in the biosynthesis of NADPH. Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of NADPH can reach up to 95%, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has four domestic and foreign NADPH patents, leading the industry. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.  Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.

A Novel Way Out of the Dilemma in the Treatment of Breast Cancer: Rh2-Lipo

Introduction Ginsenoside Rh2 nanoliposome formulation has been proved to effectively target and deliver drugs to the tumor site, with less side effects and higher treatment efficiency, holding great promise in the treatment of tumors including breast cancer. Dilemma of traditional tumor therapies The traditional tumor therapies (eg. surgery, radiation, and chemotherapy) carry the high risks of damaging normal tissues and incompletely eradicating the cancer. Strikingly, nanotechnology opens up novel opportunities for tumor treatment, which can enhance earlier diagnosis through in vitro assays, promote imaging capabilities for diagnosis and treatment monitoring, and improve therapeutic outcomes by refining targeting precision, augmenting localized drug efficacy as well as minimizing systemic toxicity. Limitations of conventional liposome formulations The conventional liposome formations encounter a lot of bottlenecks in improving the progress of tumor microenvironment, a vital complex ecosystem for cancer development and metastasis. In addition, these formulations face the trouble (eg. issues related to religion tradition and vegetarianism) brought by cholesterol, an ingredient of traditional liposomes. Moreover, there are disadvantages of complicated fabrication process, low targeting efficiency of ligand-modified liposomes as well as extended circulation time of liposomes caused by the utilization of polyethylene glycol. Merits of PTX-Rh2-Lipo PTX-Rh2-lipo, a potential nanomedicine, has an overtly smaller particle size and higher zeta potential when compared with PTX-C-Lipo. Both types of liposomes show analogous encapsulation and stabilization abilities, as manifested by similar polydispersity index, encapsulation efficiency, and loading efficiency.  Different from conventional wooden liposomes, PTX-Rh2-Lipo has the merits of enhanced uptake in tumor-associated fibroblasts L929 and 4T1 breast cancer cells, high targeting and penetration capacity, cytotoxicity against L929 fibroblasts, normalization of the vessel network, and depletion of stromal collagen. Conclusion Rh2-lipo cannot kill 4T1 breast cancer cells alone, despite of its stronger penetration ability in the tumors. Yet, it can act as a delivery vehicle for paclitaxel (PTX) to enhance its antitumor properties. Specifically, in this novel Rh2-Lipo-based nano-carrier PTX-Rh2-lipo, ginsenoside Rh2 can not only serve as a multifunctional membrane material to stabilize the structure and prolong the blood circulation of liposomes, but also works as an active ingredient to synergically enhance the efficacy of anti-cancer drugs by remodeling tumor-associated microenvironment and stimulating the immune system. Reference [1] Alrushaid N, Khan FA, Al-Suhaimi EA, et al. Nanotechnology in Cancer Diagnosis and Treatment. Pharmaceutics. 2023; 15(3):1025. doi: 10.3390/pharmaceutics15031025 [2] Hong C, Liang J, Xia J, et al. One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy. Nanomicro Lett. 2020;12(1):129. doi:10.1007/s40820-020-00472-8 [3] Hong C, Wang A, Xia J, et al. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. Int J Nanomedicine. 2024;19:2879-2888. doi:10.2147/IJN.S437733 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.

Tight Connection of NADP+/NADPH Balance with Cardiovascular Pathologies

Introduction Cardiovascular diseases (CVD) poses huge economic burden and great threat to the life of patients, even surpassing Alzheimer's disease and diabetes. 17.9 million people in the world die from CVD, with indirect treatment costs of $237 billion per year, which are projected to increase to $368 billion by 2035. It has been reported that the deficiency or imbalance of oxidized nicotinamide adenine dinucleotide phosphate (NADP+)/reduced nicotinamide adenine dinucleotide phosphate (NADPH) redox couple has been linked to a variety of pathological conditions including CVD. NADP(H) redox couple as cofactor/electron carrier in cardiommyocytes NADPH is an essential cofactor of glutathione reductase (GR) and thioredoxin reductase (TRs) in cardiommyocytes, with a crucial role in maintaining cellular redox homeostasis and energy metabolism. GR catalyzes the recycling of Glutathion (GSH) from oxidized glutathione (GSSG), and TRs reduces oxidized Trx-S2 into Trx-(SH)2. Simultaneously, both enzymes require NADPH as an electron donor and oxidize it to NADP+. Once O2•− is formed, for example, from NOXs in the cytosol and from mitochondrial electron transport chain (ETC), cytosolic CuZnSOD and mitochondrial MnSOD will reduce it to H2O2. GSH can be used by glutathione peroxidase (GPx) to reduce H2O2 further to water. Trx-(SH)2 provides reducing equivalents for Prx in the removal of H2O2. The connection of NADP(H) with cardiovascular pathologies NADP(H) plays a dual role in cardiovascular pathologies. On the one hand, the reduced NADPH can result in significant antioxidant deficiencies and intracellular accumulation of free radicals, which triggers lipid peroxidation, inflammation, and vascular dysfunction, ultimately exacerbating the course of atherosclerosisoxidase. On the other hand, high NADPH level can give rise to myocardial injury by inducing reductive stress and enhancing reactive oxygen species (ROS) production. Conclusion Changes in cellular NADP(H) content affect the intermediary metabolism of cardiac function, especially in diseased myocardium. Maintaining the balance between NADP+ and NADPH in cardiommyocytes is critically important for the treatment of CVD. Either deficiency or excess NADP(H) levels can lead to imbalances in cellular redox state and metabolic homeostasis, resulting in energy stress, redox stress, and ultimately disease state. NADP(H) has an important therapeutic value in CVD. Reference Sun Y, Wu D, Hu Q. NADP+/NADPH in Metabolism and its Relation to Cardiovascular Pathologies. Curr Med Chem. Published online February 16, 2024. doi:10.2174/0109298673275187231121054541 BONTAC NADP(H) BONTAC has dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NADP(H). Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of NADP and NADPH can reach up to 95% and 98%, respectively, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has four domestic and foreign NADPH patents, leading the industry. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.

Get In Touch

Don't hesitate to contact with us

Sending your message. Please wait...